C. N. Papandreou, D. D. Daliani, P. F. Thall, S. M. Tu, X. Wang, A. Reyes, et al., “Results of a Phase II Study with Doxorubicin, Etoposide, and Cisplatin in Patients with Fully Characterized Small-Cell Carcinoma of the Prostate,” Journal of Clinical Oncology, Vol. 20, No. 14, 2002, pp. 3072-3080. doi:10.1200/JCO.2002.12.065

has been cited by the following article:

• TITLE: Prostatic Small Cell Carcinoma: Diagnosis and Management

  AUTHORS: Parminder Singh, Amit. M. Algotar, Erika R. Bracamonte

  KEYWORDS: Prostatic Small Cell Carcinoma; Prostate Cancer; Neuroendocrine Tumor

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.3, May 27, 2013

  ABSTRACT: Prostatic small cell carcinoma (PSCC) is a distinct clinical phenotype of prostate cancer. Although rare, this phenotype is highly aggressive with very high mortality. Due to this, it is imperative for clinicians to be aware of it, diagnose it early and treat it appropriately. In this article we discuss the current literature, outline a plan for its diagnosis and management, and highlight latest research on this topic.